How immune cells regulate obesity

How immune cells regulate obesity

Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity. Now, researchers have shown how this regulation unfolds in a paper published in Nature Metabolism, which could be useful to design new treatments for the obese and overweight, and for some associated pathologies, including fatty liver disease and type 2 diabetes.

The study explains how the activation of the mitochondrial metabolism of macrophages in response to oxidative stress due to excess nutrients contributes to fatty tissue inflammation and obesity.

"In recent decades, several studies have verified that fatty tissue macrophages facilitate an anti-inflammatory and reparative environment in normal conditions. This contributes to deactivating any processes altering the normal functioning of these tissues. These are known as anti-inflammatory or 'type M2' macrophages," the senior author explains. However, in certain cases, "the M2 macrophages interpret that there are stress signals, normally arising in response to infection, and they foster inflammation as a defense mechanism."

These inflammation processes sourced to macrophages are responsible for the emergence of fatty tissue alterations, and "are the origin of obesity and the metabolic syndrome associated to cardiovascular disorders, fatty liver disease and type 2 diabetes." This means that, as a response to the excess nutrients created by a high-fat diet "macrophages change their function and support inflammatory processes, forming 'type M1' proinflammatory macrophages."

The research now published has analyzed how macrophage metabolic changes regulate this inflammatory process, which underlies obesity and the metabolic syndrome. The new findings, says another author "reveal how the detection by macrophages of oxidative danger signals -known as reactive oxygen species- leads to mitochondrial metabolism changes of these immune cells, needed to distinguish them from an M1 proinflammatory type. This oxidative stress - is found in morbidly obese patients, and it seems to be related to a high-fat diet, commonplace in the inadequate Western diet."

One of the conditions of this study, the author says, is that it proves that when this oxidative stress is reduced "it ameliorates some of the harmful parameters associated with obesity."

In previous studies, scientists had found that the Fgr protein is decisive in regulating one of the complexes of the transport chain of mitochondrial electrons -the II complex- in response to this oxidative stress, and to benefit the generation of signals (cytokines and metabolites) fostering immune responses.

Another author says that this study "proves that this same molecular mechanism regulates the conversion process of an anti-inflammatory macrophage (M2) governing the function of the tissue to a proinflammatory macrophage (M1), where lipid droplets accumulate. A balance between both types of M2/M1 macrophages is crucial for the proper functioning of the body."

Although inflammation is a normal body response and it is beneficial to face acute and transitory threats, it is very damaging when it becomes persistent or chronic, even in low-grade inflammation scenarios. The researchers explain that this happens in obesity and the metabolic syndrome, and it leads to increased cardiovascular mortality and diabetes.

The information contained in this new paper proves that, in the absence of the Fgr protein, the liver increases its ability to eliminate fat by generating ketone bodies (chemical compounds produced by ketogenesis, a process using body fats as an energy source), which are eliminated in the urine, and that this further enhances the alterations of obesity to the glucose metabolism (type 2 diabetes).

The results, found in mice, have been corroborated by human cohorts, where the authors found a stark correlation of Fgr and the negative consequences of obesity.

The researchers conclude that their data suggest the potential of using specific Fgr protein inhibitors to treat obese and/or metabolic syndrome patients. The goal would be reducing the associated inflammation, thereby improving the parameters associated with these illnesses, like fatty liver and type 2 diabetes, and contributing to raise patients' life expectancy and quality.